Health Form PROMIS10 Responsive to Patient-Reported Changes in Systemic Lupus Erythematosus

BARCELONA, SPAIN. Blonde woman at office.
Researchers evaluated the responsiveness of PROMIS10 in outpatients with SLE.

For patients with systemic lupus erythematosus (SLE), the Patient-Reported Outcomes Measurement Information Systems (PROMIS) global health short form (PROMIS10) is responsive to patient-reported changes in lupus health status, according to study results published in Arthritis Care & Research.

However, the results indicated that PROMIS10 was not responsive to clinician-assessed changes over time.

The study included patients with SLE receiving outpatient care at an academic medical center (n=223). Patients completed PROMIS10, which consisted of 7 questions related to physical, emotional, and social health, and 3 questions that evaluated emotional health, fatigue, and pain in the previous 7 days. Patients completed the survey at 2 visits a minimum of 1 month apart.

Related Articles

The researchers evaluated the responsiveness of the PROMIS10 global physical and mental health domains in patients with improvement or deterioration of health status as measured by standard validated instruments. They used Kruskal-Wallis tests to evaluate the effect size of changes in PROMIS10 scores.

Overall, 82% (n=186) of the patients completed the second set of questionnaires at a median of 3.7 months after baseline.

Baseline PROMIS10 and Short Form 36 (SF-36) scores showed poor health-related quality of life (median global physical health score, 39.8 [range, 19.9-67.7]; median global mental health score, 43.5 [range, 25.1-67.6]).

The results indicated that PROMIS10 had mild to moderate responsiveness to patient-reported improvement (effect size, 0.29) and worsening (effect sizes, -0.27 and -0.54, respectively) of health status in both global physical and mental health.

However, the researchers found that PROMIS10 changes had a poor correlation with changes in clinician-reported measures of disease activity.

Study limitations included the relatively low disease activity of patients, and the loss of approximately 18% of patients to follow-up.

“Our findings are encouraging that PROMIS10 may accurately track important disease-related patient-centered outcomes despite its brevity and global outlook, and further work is necessary to establish its responsiveness in other disease conditions and health states,” the researchers wrote.


Kasturi S, Szymonifka J, Berman JR, et al. Responsiveness of PROMIS® global health short form in outpatients with systemic lupus erythematosus [published online July 15, 2019]. Arthritis Care Res. doi:10.1002/acr.24026